Evidence map›Paper›PMID 36453240›Full record

ArticleOncology reports2023

Microcystin‑leucine arginine promotes colorectal cancer cell proliferation by activating the PI3K/Akt/Wnt/β‑catenin pathway.

Yaqi Tang, Xiaoyu Yi, Xinyu Zhang, Baojie Liu, Yongzheng Lu, Zhifang Pan, Tao Yu, Weiguo Feng

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Microcystin-LR activates serine/threonine kinases and alters the phosphoproteome in human HepaRG cells.Toxicon : official journal of the International Society on Toxinology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yaqi TangSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Xiaoyu YiSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Xinyu ZhangDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong 271000, P.R. China.
Baojie LiuSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Yongzheng LuSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Zhifang PanSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Tao YuSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Weiguo FengSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
Weifang Medical University · CNShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microcystin‑leucine arginine (MC‑LR) is an environmental toxin produced by cyanobacteria and is considered to be a potent carcinogen. However, to the best of our knowledge, the effect of MC‑LR on colorectal cancer (CRC) cell proliferation has never been studied. The aim of the present study was to investigate the effect of MC‑LR on CRC cell proliferation and the underlying mechanisms. Firstly, a Cell Counting Kit‑8 (CCK‑8) assay was conducted to determine cell viability at different concentrations, and 50 nM MC‑LR was chosen for further study. Subsequently, a longer CCK‑8 assay and a cell colony formation assay showed that MC‑LR promoted SW620 and HT29 cell proliferation. Furthermore, western blotting analysis showed that MC‑LR significantly upregulated protein expression of PI3K, p‑Akt (Ser473), p‑GSK3β (Ser9), β‑catenin, c‑myc and cyclin D1, suggesting that MC‑LR activated the PI3K/Akt and Wnt/β‑catenin pathways in SW620 and HT29 cells. Finally, the pathway inhibitors LY294002 and ICG001 were used to validate the role of the PI3K/Akt and Wnt/β‑catenin pathways in MC‑LR‑accelerated cell proliferation. The results revealed that MC‑LR activated Wnt/β‑catenin through the PI3K/Akt pathway to promote cell proliferation. Taken together, these data showed that MC‑LR promoted CRC cell proliferation by activating the PI3K/Akt/Wnt/β‑catenin pathway. The present study provided a novel insight into the toxicological mechanism of MC‑LR.

Indexed as

beta CateninColorectal NeoplasmsArginineCell ProliferationHumansLeucineMicrocystinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine KinasesArgininebeta CateninLeucineMicrocystinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine Kinasescolorectal cancermicrocystin‑leucine argininePI3K/AktproliferationWnt/β‑catenin

Identifiers

PMID36453240
PMCPMC9773010
OpenAlexW4310532679

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.